Mutations in receptors for the vitamin A metabolite retinoic acid (RAR) that repress retinoic acid (RA)-responsive gene expression have been identified and characterized. We previously reported an absence of target gene response to RA in all but one of a series of transformed human epithelial cell l
Induction of murine leukemia and lymphoma by dominant negative retinoic acid receptor α
✍ Scribed by Y. Alan Wang; Kate Shen; Yasumasa Ishida; Yaolin Wang; Akira Kakizuka; S.C. Brooks
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 351 KB
- Volume
- 44
- Category
- Article
- ISSN
- 0899-1987
- DOI
- 10.1002/mc.20144
No coin nor oath required. For personal study only.
✦ Synopsis
Acute promyelocytic leukemia (APL) is invariably associated with chromosomal translocation to retinoic acid receptor a (RARa) locus. In a vast majority of cases, RARa translocates to and fuses with the promyelocytic leukemia (PML) gene. It was thought that the fusion protein PML-RARa acts as a double dominant negative mutant to inhibit the PML and RARa signaling. In an attempt to study the physiological role of retinoic acid in mammary gland development, we created a transgenic model system expressing a dominant negative RARa under the regulation of murine mammary tumor viral promoter. We found that the transgene was also targeted to the lymphoid system in addition to mammary gland. Here we showed that dominant negative RARa induced acute lymphoblastic leukemia and lymphoma development in the transgenic mice. Retinoic acid blocked tumor development ex vivo through induction of apoptosis. Thus, our results suggested that disruption of RARa signaling was the first essential step in the development of APL in vivo.
📜 SIMILAR VOLUMES
Although attention has focused on the chemopreventive action of retinoic acid (RA) in hepatocarcinogenesis, the functional role of RA in the liver has yet to be clarified. To explore the role of RA in the liver, we developed transgenic mice expressing RA receptor (RAR) alpha- dominant negative form
Treatment of the acute promyelocytic (APL) cell line NB4 with interferon alpha (IFN(alpha)), as well as IFN(beta) and gamma, results in an increased expression of the transcripts coding for retinoic-acid receptor type alpha (RAR(alpha)) and the leukemia-specific retinoic acid receptor PML-RAR. Trans
BACKGROUND: Derivatives of retinol (vitamin A), commonly referred to as retinoids, signal through retinoic acid and retinoid X receptors (RARs/RXRs) and are essential for normal limb formation. Retinoid imbalances or perturbations in receptor function result in aberrant limb development. To examine
We and others have shown previously that retinoic acid (RA) selectively inhibits the growth of estrogen receptor (ER)-positive human breast carcinoma (HBC) cells and ER-negative cells are refractory to RA inhibition o f growth. The ER-negative cells inherently express lower levels of RARa and retino
## Abstract F9 embryonal carcinoma cells differentiate in response to retinoic acid (RA). To investigate the regulation of RA receptors (RARs) expression during this process, cDNA probes specific for the major RAR isoforms were used. In contrast to the level of RARβ2 mRNA which was high in cells tr